Drug intelligence / Profile preview

Xinsheng Helijin

Development stage: Unknown
Modality: Small Molecules

Overview

Xinsheng Helijin is a Chinese proprietary medicine developed for the treatment of male infertility, specifically targeting patients with oligozoospermia (low sperm count) and/or asthenozoospermia (reduced sperm motility). It is formulated based on traditional Chinese medicine principles and aims to improve sperm quality and DNA integrity. The drug is currently being evaluated in clinical trials for its efficacy and safety in these indications[2]. The precise herbal composition, mechanism of action, and pharmacological targets have not been disclosed in publicly available sources as of June 2025.

Brand names: Xinsheng Helijin
Other names: 欣笙禾利劲

Beyond the preview

Go deeper on Xinsheng Helijin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinsheng Helijin.

Explore the full profile